A systematic approach to evaluate humoral and cellular immune responses to Coxiella burnetii immunoreactive antigens

Chen, Chen; Bouman, Timo; Beare, Paul A.; Mertens, Katja; Zhang, G.Q.; Russell‐Lodrigue, Kasi; Hogaboam, Jason P.; Peters, Bjoern; Felgner, Philip L.; Brown, Wendy C.; Heinzen, Robert A.; Hendrix, Laura R.; Samuel, James E.

doi:10.1111/j.1469-0691.2008.02206.x

Cited by 24 publications

(30 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Felgner laboratory has also now completed the proteomes for Vaccinia virus (Davies et al, 2005a, 2007, 2008), Francisella tularensis (Eyles et al, 2007; Sundaresh et al, 2007), Burkholderia pseudomallei (Felgner et al, 2009; Yang et al, 2009), Coxiella burnetii (Beare et al, 2008; Chen et al, 2009), Chlamydia trachomatis (Molina et al, 2010) and Borrelia burgdorferi (Barbour et al, 2008) and probed a number of other viral (HIV 1 and 2, HPV, HSV-1 and 2, Dengue, Monkeypox, Varicella zoster virus, West Nile Virus, Chikungunya virus,), bacterial ( Mycobacterium tuberculosis , B. burdorferi, Brucella melitensis, Chlamydia muridarum, Salmonella typhi , Rickettsia prowazekii, Orientia tsutsugamushi, Bartonella henselae and Leptospira interrogans ) and parasitic ( Schistosomiasis japonicum and Schistosoma mansoni ; (Driguez et al, 2010) proteomes. To date, a total of 31,000 cloned genes derived from 25 infectious microorganisms have been probed against an inventory of more than 8,000 sera from infected, vaccinated and healthy people worldwide (Vigil et al, 2010a) and immunodominant antigens from each agent (see references above) as well as serodiagnostic antigens (Sundaresh et al, 2007; Beare et al, 2008; Felgner et al, 2009; Yang et al, 2009) have been identified.…”

Section: Immunomics – Integrating Genomics Proteomics and Moleculmentioning

confidence: 99%

Plasmodium immunomics

Doolan

2011

International Journal for Parasitology

View full text Add to dashboard Cite

The Plasmodium parasite, the causative agent of malaria, is an excellent model for immunomic-based approaches to vaccine development. The Plasmodium parasite has a complex life cycle with multiple stages and stage-specific expression of ~ 5,300 putative proteins. No malaria vaccine has yet been licensed. Many believe that an effective vaccine will need to target several antigens and multiple stages, and will require the generation of both antibody and cellular immune responses. Vaccine efforts to date have been stage-specific and based on only a very limited number of proteins representing < 0.5% of the genome. The recent availability of comprehensive genomic, proteomic and transcriptomic datasets from human and selected non-human primate and rodent malarias provide a foundation to exploit for vaccine development. This information can be mined to identify promising vaccine candidate antigens, by proteome-wide screening of antibody and T cell reactivity using specimens from individuals exposed to malaria and technology platforms such as protein arrays, high throughput protein production and epitope prediction algorithms. Such antigens could be incorporated into a rational vaccine development process that targets specific stages of the Plasmodium parasite life cycle with immune responses implicated in parasite elimination and control. Immunomic approaches which enable the selection of the best possible targets by prioritizing antigens according to clinically relevant criteria may overcome the problem of poorly immunogenic, poorly protective vaccines that has plagued malaria vaccine developers for the past 25 years. Herein, current progress and perspectives regarding Plasmodium immunomics are reviewed.

show abstract

Section: Immunomics – Integrating Genomics Proteomics and Moleculmentioning

confidence: 99%

Plasmodium immunomics

Doolan

2011

International Journal for Parasitology

View full text Add to dashboard Cite

show abstract

“…This reactivity can be readily blocked using E. coli lysate, thereby revealing the antigen-specific signal. This relatively simple approach has been successfully applied to the discovery of antibody targets in the ORFeomes of several pathogens, including vaccinia virus [51][52][53][54], M. tuberculosis [11], Plasmodium falciparum [13,55,56], Brucella melitensis [57], Chlamydia trachomatis [58], Francisella tularensis [59,60], Burkholderia pseudomallei [9], Coxiella burnetii [61][62][63], Borrelia burgdorferi [64], Bartonella henselae [65], Toxoplasma gondii [66], Candida albicans [67], Schistosoma mansoni [14] Schistosoma japonicum [14], and HPV [68].…”

Section: Nitrocellulose Substrate Arraysmentioning

confidence: 99%

Antigen Discovery for Vaccines Using High‐Throughput Proteomic Screening Technologies

Davies¹

2012

Vaccinology

View full text Add to dashboard Cite

“…The Protein Microarray Laboratory at UC Irvine has developed a highly efficient method to determine the humoral immune response to microbial antigens. We have applied this approach to more than 30 medically important infectious microorganisms [3–33] including M. tuberculosis [33], Plasmodium falciparum [5,8,24], Plasmodium vivax , Brucella melitensis[ 14], Chlamydia trachomatis [3,25], Francisella tularensis [11,23], Burkholderia pseudomallei [6,19], Coxiella burnetii [7,26], Borrelia burgdorferi [10], Salmonella enterica typhi, Rickettsia prowazekii, Rickettsia rickettsii, Orientia tsutsugamushi, Bartonella henselae [17], Leptospira interrogans, Toxoplasma gondii [27], Candida albicans [28], Schistosoma mansoni [4] and viruses including vaccinia[9,29–31], monkeypox, Herpes 1 & 2, Varicella zoster, HPV[32], HIV, Dengue, influenza, West Nile and Chikungunya. Since launching this project 10 years ago we have made more than 40,000 plasmids, printed the encoded proteins on 25,000 microarrays and probed the arrays with 15,000 serum specimens in order to determine disease associated antibody profiles in people infected with each agent.…”

Section: Introductionmentioning

confidence: 99%

A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases

Liang

Felgner

2015

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review: There is a need for improved diagnosis and for more rapidly assessing the presence, prevalence and spread of newly emerging or re-emerging infectious diseases. An approach to the pathogen-detection strategy is based on analyzing host immune response to the infection. This review focuses on a protein microarray approach for this purpose. Recent findings: Here we take a protein microarray approach to profile the humoral immune response to numerous infectious agents, and to identify the complete antibody repertoire associated with each disease. The results of these studies lead to the identification of diagnostic markers and potential subunit vaccine candidates. These results from over 30 different organisms can also provide information about common trends in the humoral immune response. Summary: Systems biology approach to identify the antibody repertoire associated with infectious diseases challenge using protein microarray has become a powerful method in identifying diagnostic markers and potential subunit vaccine candidates, and moreover, in providing information on proteomic feature (functional and physically properties) of seroreactive and serodiagnostic antigens. Combining the detection of the pathogen with a comprehensive assessment of the host immune response will provide a new understanding of the correlations between specific causative agents, the host response, and the clinical manifestations of the disease.

show abstract

A systematic approach to evaluate humoral and cellular immune responses to Coxiella burnetii immunoreactive antigens

Cited by 24 publications

References 5 publications

Plasmodium immunomics

Plasmodium immunomics

Antigen Discovery for Vaccines Using High‐Throughput Proteomic Screening Technologies

A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases

Contact Info

Product

Resources

About